戻る Agenda
S21 : Toward Tomorrow’s Norm: Patient-Driven Drug Development through Collaboration with Academia and Emerging Biopharma
Session Chair(s)
Junko Sato, PhD
Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Speaker(s)
Midori Senoo
Myotonic Dystrophy Patients' Group of Japan, Japan
Managing Director
Harumasa Nakamura, MD, PhD
National Center of Neurology and Psychiatry, Japan
Director of Department of Clinical Research Support,
Haruhiko Morita
Modalis Therapeutics Corporation, Japan
President and Chief Executive Officer (CEO)
Michiyo Ohshima, MBA
Pfizer R&D GK, Japan
Senior Director, Head of Japan Portfolio and Project Management